Short answer
Outset Medical, Inc. (OM) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $32M (up 0.7% year over year) with net income of −$18M.
Q2 2026 key financials · XBRL
- Revenue
- $32M
- +0.7% YoY · +13.5% QoQ
- Net income
- −$18M
- +3.0% YoY · +5.2% QoQ
- Operating margin
- -49.6%
- Gross margin
- 42.0%
- EPS (diluted)
- −$0.97
- −1177.8% YoY · +5.8% QoQ
Source: XBRL data from the Outset Medical, Inc. (OM) Q2 2026 10-Q on SEC EDGAR. USD.
Outset Medical, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $31.635M, up 1% YoY from $31.419M
- Service revenue $9.727M, up 17% YoY; product revenue $21.908M, down 5%
- Gross margin 42.0% vs 37.8% YoY; operating loss $15.676M vs $16.865M
- Cash, equivalents, restricted cash and short-term investments $151.0M at June 30, 2026
- Six-month operating cash outflow $22.479M vs $30.486M; management expects operating losses near term
Risk Factors
- Newly triggered regulatory risk: Q3 2026 FDA inspection of San Jose facility produced a Form FDA-483 with inspectional observations
- Most materially updated risk: potential follow-on FDA communications or actions, with costly remediation and possible operating restrictions
- Compliance risk: QMSR or supplier noncompliance could cause recalls, clearance withdrawals, production shutdowns, or penalties
- Operational risk: supplier regulatory failures could delay Tablo production or prevent required quantities
- Financial risk: August 5, 2026 credit amendment changed trailing-twelve-month net-revenue covenants and reset warrant exercise price to $4.838
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Outset Medical, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.